Objective: To investigate the protective effect of Paidu Baoshen pills and valsartan on residual renal function (RRF) of patients with peritoneal dialysis. Method: Totally seventy-six cases treated with peritoneal dialysis in our hospital between January 2012 and March 2014 were included and divided into two groups by using the hidden random number table method. The 38 cases in the control group were given valsartan and basic western treatment beside the peritoneal dialysis

while the 38 patients in the study group took Paidu Baoshen pills developed by our hospital on beside the therapies of the control group. The treatment lasted for 12 weeks (four weeks in one course of treatment). Their residual renal function indexes after the treatment

dialysis related indexes before and after the treatment and other relevant indexes of the two groups were observed

the curative effect was evaluated after three courses of treatment. Result: At the 4th

8th and 12th week after the dialysis

both groups showed reduction in 24 h urine volume

and the study group showed significantly lower RRF and 24 h urine volume than the control group (P <0.05)

at the 12th week after the treatment

both groups showed obviously lower urea nitrogen (BUN) than before the treatment

while the study group showed notably lower serum creatinine (SCr) than before the treatment (P <0.05)

the study group showed significantly lower BUN and SCr than the control group (P <0.05)

the study group shower significantly higher Hb and Alb before the treatment (P <0.05)

with a higher rate than the control group and significant differences between groups (P <0.05)

both groups showed significant reduction in the entire section of parathyroid hormone (iPTH) compared with that before the treatment (P <0.05)

with no significant difference in the decrease rate between the groups (P <0.05). The study group showed a total effective rate of 71.05%

which was significantly higher than the control group (P <0.05). Conclusion: Paidu Baoshen pills combined with valsartan can delay the decreases in RRF and urine volume of patients with peritoneal dialysis and relieve anemia

with a protective effect on residual renal function of patients with peritoneal dialysis.